SuperGen, Inc. (NASDAQ:SUPG), a pharmaceutical company dedicated to the discovery and development of novel cancer therapies, announced that its chairman, president and chief executive officer, James S.J. Manuso, Ph.D., has been elected to the Full Board of Directors of the Biotechnology Industry Organization (BIO) at its 2011 International Convention.
“I am honored to serve on the BIO Board of Directors,” said Dr. Manuso. “Collaborating with such an esteemed group of international life sciences leaders on health policy affecting oncology patients and those with other serious illnesses will hopefully enhance the effectiveness with which medical therapies are discovered, approved, and delivered.”
BIO’s Board of Directors is composed of members of the Governing Boards for each of BIO’s four sections: Health, Emerging Companies, Industrial & Environmental and Food & Agriculture. Dr. Manuso will serve on BIO’s Health Section Governing Board.
“I want to welcome Dr. Manuso to the Board, we are proud that he will be serving on BIO’s Full Board of Directors and on the Health Section Governing Board,” said Jim Greenwood, President and CEO of BIO. “His expertise and experience will be highly valuable to BIO’s critical policy development and advocacy activities.”
In addition, Dr. Manuso will serve on the BIO Board Standing Committee on International Affairs.
SuperGen has been a member of BIO since 2003. In addition to Dr. Manuso’s appointment to the Board, Nancy Worrell, SuperGen executive director, human resources, is the Co-Chair of the BIO Human Resources Conference 2011. The BIO Human Resources Conference 2011 has integrated events and offerings from the BIO International Convention.
About James S.J. Manuso, Ph.D.
Dr. Manuso has served as SuperGen chairman, president and chief executive officer since January 1, 2004, as chief executive officer-elect from September 2003 to December 2003 and as a director since February 2001. He is co-founder and immediate past president and chief executive officer of Galenica Pharmaceuticals, Inc.